Literature DB >> 1280700

Demonstration of plasma proteinase inhibitors in beta 2-microglobulin amyloid deposits.

J M Campistol1, T Shirahama, C R Abraham, O G Rodgers, M Solé, A S Cohen, M Skinner.   

Abstract

beta 2-microglobulin-related amyloidosis (A beta 2M) represents a frequent complication in long-term dialysis patients. Although the pathogenetic mechanism has yet to be fully understood, it is known that amyloid fibrils usually consist of intact molecules of beta 2-microglobulin (beta 2m). Plasma proteinase inhibitors (PPI) are a broad family of glycoproteins with the function of eliminating unwanted proteolysis of serine proteases. Their role in amyloidogenesis has become a subject of intense discussion, especially since the recent identification of alpha 1-antichymotrypsin in the beta-protein amyloid deposits of Alzheimer's disease. We evaluated immunohistochemically and biochemically the presence and distribution of several PPIs (alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-macroglobulin and tissue inhibitor metalloproteinase) and amyloid P component in A beta 2M deposits in osteo-articular and visceral tissues from dialysis patients with amyloidosis, as well as two carpal tunnel synovia from non-dialysis patients and one Alzheimer's brain as controls. The immunohistochemical study demonstrated that all but one (anti-alpha 1-antichymotrypsin) of the PPI antibodies tested showed varying degrees of positive reaction against A beta 2M deposits. All the antibodies (including anti-alpha 1-antichymotrypsin) also reacted to some extent with other non-amyloid visceral and connective tissue elements diffusely and/or selectively. Among them, only the reaction of anti-amyloid P component had significantly distinctive localization to A beta 2M deposits, which were identified in adjacent serial sections by Congo red staining and immunohistochemical reaction against anti-beta 2m.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280700     DOI: 10.1038/ki.1992.368

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  3 in total

Review 1.  Clinical and pathogenic factors in dialysis-related amyloidosis: current research findings.

Authors:  F Gejyo
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

2.  Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin.

Authors:  C Aprile; G Marinone; R Saponaro; C Bonino; G Merlini
Journal:  Eur J Nucl Med       Date:  1995-12

Review 3.  Systemic amyloidosis: lessons from β2-microglobulin.

Authors:  Monica Stoppini; Vittorio Bellotti
Journal:  J Biol Chem       Date:  2015-03-06       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.